Across TCGA pan-cancer cohorts, MIR302A RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of MIR302A’s most consistent transcriptional readouts.
The strongest signal is observed in stomach adenocarcinoma (STAD), where MIR302A RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MIR302A is over-expressed in tumor.
STAD and PRAD are the cancer types where MIR302A tumor–normal differential expression is most reproducible.